Nicole Sheahan, President of the Global Colon Cancer Association, shared a post on LinkedIn:
“Final Board meeting of 2025 for From Testing to Targeted Treatments (FT3) officially in the books! It is inspiring to see how far this initiative has come in just five years and how it continues to evolve with the rapid progress of precision medicine.
FT3 is focused on making personalized healthcare usable and accessible to everyone who can benefit. Anchored in both expertise and humanity, the program champions co-creation and meaningful collaboration across global and disciplinary boundaries.
I have had the privilege of serving on the FT3 Board since 2022 and on the Executive Committee for just over a year. It has been an honor to work alongside dedicated partners who share a commitment to improving outcomes for patients worldwide. As we look to 2026, I am energized by the work ahead and grateful to contribute to an initiative that truly puts people at the center of precision medicine. Learn more.
Special thanks to Helena Harnik, Executive Director, my colleagues on the Executive Committee: Denis C. and Ralph Riley, and the full board of directors:
Jeanie Hsieh, Maria Karasarides, James Creeden, Barry D. Stein, Lee-Anne Zinetti, Linda Murakami, Bahija Gouimi, Celia Diez de los Ríos, Charles Alessi, Petra ADÁMKOVÁ, Razelle Kurzrock, Catalina Lopez-Correa, Runcie C.W. Chidebe, Ivica Belina, Susan McClure, Durhane Wong-Rieger, Umberto Malapelle.”
More posts featuring Nicole Sheahan.